Vascular abnormalities common following intravitreal bevacizumab for ROP

• Posted on: Feb 26 2019
• By: Saratoga Opthalmology
• Leave a response

Researchers report the regression patterns experienced by patients after off-label intravitreal bevacizumab therapy for retinopathy of prematurity (ROP).
Source: AAO

Posted in: Uncategorized